NexGem

The European Medicines Agency has approved Cullinan Therapeutics' Clinical Trial Application for CLN-978, a CD19xCD3 bispecific T cell engager, to begin Phase 1 trials in rheumatoid arthritis patients.

Cullinan Management's zipalertinib met its primary endpoint in a Phase 2b trial for non-small cell lung cancer (NSCLC), demonstrating a promising overall response rate.

Arvinas plans to initiate two Phase 3 trials in 2025 for vepdegestrant in ER+/HER2- metastatic breast cancer, one in the first-line setting with atirmociclib and another in the second-line setting with a CDK4/6 inhibitor.

UChicago Medicine launched a Phase 2 clinical trial to explore CAR T-cell therapy for systemic lupus erythematosus, inflammatory myositis, and systemic sclerosis.

Cullinan Therapeutics has received approval to initiate a global Phase 1 clinical trial of CLN-978 for systemic lupus erythematosus (SLE).